Apixaban Enhances Endogenous Fibrinolysis

in Patients with Atrial Fibrillation

Short Title: Effect of Apixaban on endogenous fibrinolysis

Nikolaos Spinthakis MB BS, MRCP^{1,2}, Ying Gue MB BS, MRCP^{1,2}, Mohamed Farag MB, BS, PhD^{1,2}, Manivannan Srinivasan MB BS, MD, FRCP², David Wellsted PhD¹, Deepa RJ Arachchillage MD^{3,4}, Gregory Y.H. Lip MD, FRCP⁵*, Diana A Gorog MD, PhD, FRCP^{1,2,6}*

Word count 4550 (inc. references)

- 1. Postgraduate Medical School, University of Hertfordshire, Hertfordshire, United Kingdom
- 2. Department of Cardiology, East and North Hertfordshire NHS Trust, Hertfordshire, United Kingdom
- 3. Royal Brompton Hospital, London, United Kingdom
- 4. Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom
- Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, United Kingdom; and Aalborg Thrombosis Research Unit, Department of Clinical Medicine, Aalborg University, Aalborg, Denmark
- 6. National Heart & Lung Institute, Imperial College, London, United Kingdom

[*joint senior authors]

Correspondence:

Prof. Diana A Gorog MB BS, MD, PhD, FRCP National Heart and Lung Institute Dovehouse Street London SW3 6LR United Kingdom Tel +44 (0)207 034 8934; Fax +44 (0)207 0348935 <u>d.gorog@imperial.ac.uk</u>

Acknowledgement and funding

This study was supported by a grant from ERISTA (BMS/Pfizer European Thrombosis Investigator Initiated Research Program, BMS protocol number: CV185-622). The investigators acknowledge the support of the U.K. National Institute for Health Research Clinical Research Network (NIHR CRN).

Disclosures

GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Novartis, Verseon and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, and Daiichi-Sankyo. No fees are directly received personally. DAG: Related through family to a director in Thromboquest Ltd. but no personal or institutional research sponsorship received from this company, and instrument and consumables purchased through normal commercial transactions. Speaker/honoraria from Bayer, BMS, Abbott. DRJA received sponsorships to attend national and international meetings from Bayer, Boehringer Ingelheim.

Other co-authors have no conflicts to declare.

ABSTRACT

Background Approximately 20% of ischaemic stroke patients exhibit spontaneous arterial recanalization, attributable to endogenous fibrinolysis, which strongly relates to improved functional outcome. The impact of oral anticoagulants on endogenous fibrinolysis is unknown.

Objective Our aim was to test the hypothesis that apixaban enhances endogenous fibrinolysis in non-valvular AF (NVAF).

Methods In a prospective cross-sectional analysis, we compared endogenous fibrinolysis in NVAF patients (n=180) taking aspirin, warfarin or apixaban. In a prospective longitudinal study, patients were tested before and after apixaban (n=80). Endogenous fibrinolysis was assessed using the Global Thrombosis Test (GTT) and Thromboelastography (TEG). *Results* Endogenous fibrinolysis (measured by GTT lysis time [LT]) was shorter on apixaban compared to warfarin or aspirin (median 1850[IQR 1591-2300] vs. 2758[2014-3502] vs. 2135[1752-2463] sec, p<0.0001). Among TEG indices, a small but significant difference in clot lysis time (CLT) was observed (apixaban 60.0[45.0-61.0] vs. warfarin 61.0[57.0-62.0] vs. aspirin 61.0[59.0-61.0] min, p=0.036). Apixaban improved endogenous fibrinolysis measured using the GTT (LT pre-treatment 2204[1779-2738] vs. on-treatment 1882[1607-2374] sec, p=0.0003), but not by using TEG. Change in LT (Δ LT) with apixaban correlated with baseline LT (r=0.77, p<0.0001). There was weak correlation between Δ LT and Δ CLT in response to apixaban (r=0.28, p=0.02) and between on-apixaban LT and CLT (r=0.25, p=0.022).

Conclusions Apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer

additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.

Word count 248

Key words:

Endogenous fibrinolysis, thrombosis, apixaban, atrial fibrillation, NOAC.

Abbreviations:

AF atrial fibrillation CLT clot lysis time CV coefficient of variation GTT Global Thrombosis Test LT lysis time NOAC non-vitamin K antagonist oral anticoagulants NVAF non-valvular atrial fibrillation OT occlusion time TEG Thromboelastography VKA vitamin K antagonist

Introduction

Spontaneous fibrinolysis is an important defence mechanism against downstream infarction following occlusive arterial thrombosis. In patients with acute stroke, spontaneous arterial recanalization is observed in 17–24% of patients and is strongly related to improved functional outcomes. Importantly, *ex vivo* endogenous fibrinolysis has been shown to be significantly impaired in patients with stroke compared to normal volunteers¹. Impaired endogenous fibrinolysis has also been shown to be marker of recurrent thrombotic risk in patients with acute coronary syndrome² and end-stage renal failure³.

Patients with atrial fibrillation (AF) frequently exhibit impaired endogenous fibrinolysis and preliminary data indicate that this state improves after successful restoration of sinus rhythm with radiofrequency ablation⁴. A review of the importance of endogenous fibrinolysis in determining clinical outcomes concluded that global assays, assessing proaggregatory and fibrinolytic pathways, could aid in identifying impaired fibrinolysis as a potential target for pharmacological modulation³.

Currently, there is no available oral pharmacotherapy to favourably modulate fibrinolytic status where this is impaired. Beside the use of plasminogen activators to achieve acute thrombolysis in the setting of acute myocardial infarction and stroke, pharmacological options to manipulate the fibrinolytic state are limited. Our preliminary data indicate that the non-vitamin K antagonist oral anticoagulants (NOACs) may enhance endogenous fibrinolysis in patients with AF, with significant effect observed only with apixaban⁴. In our pilot data in 20 patients, apixaban enhanced endogenous fibrinolysis, evidenced by a significant reduction in endogenous fibrinolysis time. However, it is noteworthy that with all NOACs, there was a

6

trend to favourably enhancing endogenous fibrinolysis and perhaps if the sample size had been sufficiently large, a significant effect may have been observed. Neither warfarin, nor aspirin or clopidogrel, have been shown to enhance endogenous fibrinolysis.

Nevertheless, the impact of pharmacotherapy on the effectiveness of the spontaneous endogenous fibrinolytic pathway has been difficult to measure, due to lack of available techniques. Factorial assays such as plasminogen activator inhibitor 1, tissue plasminogen activator and thrombin activatable fibrinolysis inhibitor cannot provide a reflection of the *overall* state of endogenous fibrinolysis³. There are currently 2 point-of-care techniques that provide a global assessment of thrombus formation and fibrinolysis, namely thromboelastography (TEG or ROTEM), which uses citrated or whole blood, and the Global Thrombosis Test (GTT), using non-anticoagulated blood. The determinants of the results of these global tests of fibrinolysis are the thrombus properties (clot strength, determined by the thickness, density, and pore size of fibrin strands) and the rate of fibrinolysis.

We hypothesised that there was beneficial effect of apixaban on endogenous fibrinolysis in patients with NVAF. To test this hypothesis, we performed a cross sectional study of NVAF patients treated with apixaban, warfarin or aspirin. Second, we assessed the impact of initiating apixaban.

Methods

We conducted a prospective, observational (non-randomised) study in 200 stable out-patients with non-valvular atrial fibrillation (NVAF), approved by the National Research Ethics Service and the UK Health Research Authority (ClinicalTrials.gov identifier: NCT03199521). All subjects gave written informed consent and the study was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.

The study comprised 2 arms; a longitudinal arm (n=80) and a cross-sectional arm (n=180), with 60 patients on apixaban taking part in both. In the prospective longitudinal study, 80 patients with newly diagnosed NVAF were recruited, who were scheduled to start anticoagulation with apixaban for thromboprophylaxis of stroke and systemic embolism and who were studied before and during apixaban treatment. In the cross-sectional study, 180 patients with known NVAF already established on treatment with one of aspirin (n=60), warfarin (n=60) or apixaban (n=60) for thromboprophylaxis of stroke and systemic embolism. Were studied in an observational study, where drug allocation was by physician choice, and not randomised.

The following exclusion criteria were applied: age <18 years; significant hepatic or renal impairment likely to cause a bleeding diathesis; patients taking antiplatelet or anticoagulant therapy (except for patients taking part in the cross-sectional study), systemic steroids or immunosuppression; known active malignancy; bleeding diathesis; blood dyscrasia (platelets <70 x10⁹/L, haemoglobin <80g/L, international normalized ratio [INR] >1.4; activated partial thromboplastin time [aPTT] more than twice upper limit of normal; leukocyte count <3.5x10⁹/L, neutrophil count <1x10⁹/L); active alcohol or substance abuse; those involved in

8

another investigational trial of a medicine or medical device; those unable or unwilling to provide consent.

Antithrombotic therapy

The choice of oral antithrombotic therapy was decided by the clinical care team. Apixaban was given at a dose of 5mg b.i.d. (or 2.5 mg b.i.d. in patients with two or more of the following: age \geq 80 years, weight \leq 60 kg, serum creatinine \geq 133 µmol/L). In the longitudinal study, blood samples were taken before (i.e. non-anticoagulated) and after patients were established on uninterrupted apixaban treatment for at least 4 weeks. For the cross-sectional study, blood samples were obtained after patients had been established on treatment for at least 4 weeks. Patients taking warfarin were tested after at least three previous consecutive INR readings within the therapeutic range (2.0-3.0).

Blood sampling

Venous blood samples were obtained from an antecubital vein using an 18-G butterfly cannula and a two-syringe technique. The first 5 ml was used for routine blood tests and the second 10 ml used for assessment of thrombotic status and apixaban levels measured using drug-specific calibrators (anti-Xa [FXa] level). Blood samples were taken 4-6 hours after the last dose of apixaban. Fasting was not required.

Assessment of thrombotic status including endogenous fibrinolysis

Global Thrombosis Test

Thrombotic status was assessed using the point-of-care Global Thrombosis Test (GTT, Thromboquest Ltd., London, UK), which assesses overall thrombotic status, including platelet reactivity, coagulation and endogenous (spontaneous) thrombolysis. which assesses both platelet reactivity to high shear stress and endogenous fibrinolysis². The test was performed on native, non-anticoagulated whole blood within 15 s of withdrawal. The instrument assesses firstly the time taken to form an occlusive thrombus under high shear, which is a marker of platelet reactivity (occlusion time, OT). Shorter occlusion time represents enhanced platelet reactivity. Following the arrest of flow due to the formation of an occlusive platelet thrombus crosslinked by fibrin strands. Following a short stabilisation period, the instrument records the time required to dissolve the thrombus formed in the first phase, through endogenous fibrinolysis, which manifests in restart of flow (lysis time, LT). Longer lysis times represent less effective endogenous fibrinolysis. In addition, the GTT measures thrombus stability by measuring the number of rebleeds (number of drops, D) after OT until the compete occlusion and final arrest of flow. The intra-assay and inter-assay coefficients of variation (CV) for OT and LT were assessed in 10 subjects on repeated sampling and also running samples in parallel.

Thromboelastography

Venous blood was also assessed with thromboelastography (TEG 5000 Hemostasis Analyser System, Haemonetics, Watford, UK). Two tests were performed in parallel for each patient, one using non-citrated whole blood tested immediately after withdrawal and one using noncitrated whole blood with the addition of kaolin activator after four minutes, according to the manufacturer's instructions. The TEG assesses platelet-independent clot formation, fibrinogen contribution to clot integrity (R, K, A, MA, TMA) as well as the primary fibrinolytic potential of the clot (LY30, LY60, CLT) (Table 3). The intra-assay and interassay coefficients of variation (CV) for all TEG parameters were assessed in 10 subjects on repeated sampling and running samples in parallel for the whole blood alone and with kaolin activator.

Apixaban (anti-FXa) levels

In patients taking apixaban, samples were taken for apixaban level at the same time as blood draw for thrombotic status assessment. Apixaban level was measured using HemosIL Liquid Heparin kit (Werfen UK, Birchwood, Warrington, Cheshire, UK) on ACL TOP500 analyser using drug-specific callibrators. Based on population pharmacokinetics studies on patients taking apixaban 5mg b.i.d. for stoke prevention in NVAF, peak and trough levels of apixaban (measured as anti-FXa levels) have been reported as 171ng/ml (91-321) and 103ng/ml (41-230) respectively⁵. Anti-FXa levels were assessed by an independent investigator blinded to GTT and TEG results.

Study endpoints

The primary endpoint was the change in thrombotic status, in particular endogenous fibrinolysis, in response to apixaban in the longitudinal study. The secondary endpoint was a comparison of endogenous fibrinolysis in patients established on different antithrombotic treatments (apixaban, warfarin, aspirin) in the cross-sectional study.

Sample size and statistical analysis

Results from our pilot study⁴ showed a 24% relative reduction in endogenous fibrinolysis time with apixaban with a medium effect size (r=0.4, z=2.763, p=0.006). Using a two-tailed t test, we calculated that a sample size of 78 patients would be required to detect a 24% relative reduction with 90% power based on an effect size of 0.4 and α =0.05 (longitudinal study). For the cross-sectional study, it was assumed that endogenous fibrinolysis in patients

taking warfarin and aspirin would be similar, based on our earlier pilot showing no change in endogenous fibrinolysis in response to warfarin (8). Assuming a one-tailed independent group comparison and an effect size of 0.4, a total of 180 patients were required to give α =0.05 to achieve 80% power.

Data are presented as mean±standard deviation when normally distributed, or as median (interquartile range), when non-normally distributed. Dichotomous variables were compared using chi-square test. Paired comparison between groups was evaluated with paired t-test and Wilcoxon ranked sum test. The analysis of variance (ANOVA) or Kruskal-Wallis test were used to assess differences between groups. To investigate the relationship between the change in fibrinolysis in response to apixaban and baseline characteristics, univariate and multivariate regression models were used. All variables were analysed using univariate regression; clinically relevant parameters and those shown to be significant ($p \le 0.05$) were entered into the multivariate model. In a post hoc analysis, the model's assumptions were tested and the residuals were normally distributed. Regression models were used to illustrate the linear prediction between change in LT (Δ LT) and baseline LT. Correlations were analysed using Pearson's and Spearman's methods. Analyses were performed with Stata version 15.1 (StataCorp, College Station, TX, USA).

Results

Between June 2017 and May 2018, 270 patients were screened and 200 patients recruited. Clinical characteristics of patients in the longitudinal study are presented in Table 1 and those in the cross-sectional study in Table 2. For the GTT, the intra-assay CV for OT was 6% and for LT 8%, and the inter-assay CV was 7% for OT and 9% for LT. The average intra-assay CV for TEG was 22% using native blood and 20% for native blood with kaolin.

Effect of apixaban on thrombotic status including endogenous fibrinolysis

Distributions of OT and LT pre- and during apixaban treatment are shown in Figure 1. Compared to baseline, apixaban significantly prolonged OT [361 ± 112 vs. 463 ± 124 sec, p<0.0001]. The number of drops (D) did not change in response to apixaban treatment [2.5 ± 1.7 vs. 3.1 ± 1.6 , p=0.173]. There was moderate inverse correlation between the change in OT in response to apixaban (Δ OT) and baseline OT (r=-0.4, p=0.0002).

Compared to baseline, LT on apixaban was significantly shorter (2204[1779-2738] vs. 1882[1607-2374] sec, p=0.0003). There was no correlation between baseline OT and baseline LT (p=0.740) or between on-treatment OT and on-treatment LT (p=0.241).

Apixaban did not alter TEG indices, except for a small reduction in the rate of clot formation with kaolin (68.4° vs. 67°, p=0.026) (Tables 3 and 4).

Baseline OT and LT did not correlate with any of the baseline TEG indices with or without kaolin. In particular, baseline fibrinolysis assessment (LT) with the GTT did not correlate with any of the baseline TEG indices of fibrinolysis (LY30, LY60 and CLT). On-treatment OT did not correlate with any on-treatment TEG indices. There was a significant correlation between Δ OT and the change in reaction time (R) with kaolin in response to apixaban (r=0.54, p<0.0001). There was a weak correlation between on-treatment LT in GTT correlated with clot lysis time (CLT) in the TEG (r=0.25, p=0.022). There was weak correlation between Δ LT and the change in kaolin CLT (Δ CLT) in response to apixaban (r=0.28, p=0.02).

Magnitude of effect of apixaban in relation to baseline fibrinolysis

The change in LT in response to apixaban (Δ LT) correlated closely with baseline LT (r=0.77, p<0.0001). The magnitude of effect of apixaban on reducing LT was greatest in those with the longest LT at baseline (Figure 2). Patients on apixaban were grouped into quartiles based on baseline LT to assess the magnitude of change in LT with apixaban (Table 1). The Δ LT between the four groups was significantly different (p<0.0001).

Cross-sectional comparisons of apixaban, warfarin and aspirin

Measures of thrombotic status assessed with GTT and TEG are shown in Table 5. LT was significantly lower in patients taking apixaban than other medications. From the TEG indices, only native CLT was significantly lower in the apixaban group compared to patients on warfarin and aspirin. Multivariable regression models were applied to account for baseline differences in the three groups. After accounting for these variables (Table 2) both OT and LT remained significantly different between the apixaban and the warfarin arms (p<0.0001).

Relationship of thrombotic effect to apixaban levels

Apixaban levels in patients taking 5mg b.i.d. was C_{max} 152.9 ng/ml (32.9-317.9 ng/ml), and in patients taking the 2.5mg b.i.d. dose was C_{max} 125.85 ng/ml (40.6-344.6 ng/ml). Apixaban levels correlated weakly with OT on apixaban (r=0.27, *p*=0.022) but not with LT. There were no significant relationships between apixaban levels and TEG parameters.

DISCUSSION

In this study, our principal findings are as follow: (i) Apixaban significantly improved endogenous fibrinolysis, and the effect of apixaban was greatest in those patients with the longest lysis time at baseline; and (ii) In comparison to patients on warfarin or aspirin, patients taking apixaban exhibited more rapid (more effective) endogenous fibrinolysis.

These observations may have clinical relevance, given that effectiveness of endogenous fibrinolysis is an important determinant of the clinical outcome of a thrombotic stimulus. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients who have impaired fibrinolysis, compared to warfarin, requires further study. Importantly, the finding that apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin does not mean that apixaban by itself exhibits a more favourable fibrinolysis profile as compared to aspirin and warfarin.

In our current study, 23% of patients with NVAF had significantly prolonged lysis time before the start of anticoagulation (defined as baseline LT>3000 sec, based on prior data)³. Such impaired endogenous fibrinolysis in patients with acute coronary syndromes has been associated with increased risk of cardiovascular death and recurrent MI^{2,3,5}. Dual antiplatelet therapy post-ACS did not appear to reduce LT. The average 15% reduction in fibrinolysis time with apixaban seen here is potentially clinically significant, but even greater effect, up to 48% reduction in LT was seen in those with the most impaired fibrinolysis at baseline. If apixaban were to exert similar reduction in LT in patients with ACS, as that observed here in NVAF, that would be expected to reduce the risk of MACE in those with prolonged LT at baseline. Our observations suggest that further study in controlled trials could investigate

15

whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin.

The effect of improving fibrinolytic status with apixaban appears not to be simply an anticoagulant effect, since patients on apixaban had more rapid fibrinolysis than patients therapeutically anticoagulated with warfarin, and there was no relation between apixaban levels and LT. Apixaban levels in our study were similar to those previously reported⁵ and are known to correlate closely with anti-FXa activity. In the ARISTOTLE trial, apixaban was as effective as warfarin in reducing the risk of ischaemic stroke and systemic embolism in NVAF, whilst the AVERROES study showed that apixaban was superior to aspirin⁶. Both ARISTOTLE and AVERROES suggest a greater benefit of apixaban, compared to warfarin, in reducing ischaemic stroke and systemic embolism in patients with CHADS₂ score \geq 3 than in patients with lower CHADS₂ scores, suggesting apixaban may have additional advantages in the highest risk patients. Although in the ARISTOTLE trial comparing apixaban with warfarin in NVAF, the secondary endpoint of combined ischaemic or uncertain type (not clearly haemorrhagic or ischemic) stroke was non-significantly different with both anticoagulants⁷, a subgroup analysis of patients with previous stroke or TIA showed the rate of stroke or systemic embolism was significantly lower with apixaban than with warfarin, suggesting that the absolute benefits of apixaban might be even greater in high-risk patients⁸. In the largest realworld retrospective analysis of ~77,000 patients with NVAF, apixaban use was associated with significantly lower risk of stroke and systemic embolism than warfarin⁹.

Apixaban is a direct inhibitor of free and clot- or prothrombinase-bound FXa and, thereby, prevents thrombin generation. Thrombin is not only a key protein in fibrin clot formation, but also the most potent activator of platelet aggregation *in vivo*¹⁰ and an important determinant

of the strength and stability of the fibrin clot and its resistance to fibrinolysis¹¹. Apart from reduced thrombin generation, FXa inhibition with apixaban might also impact platelet haemostasis by blocking the direct effects of FXa via protease activator receptor signalling¹⁰. Nevertheless, studies assessing the effect of FX inhibition on platelet reactivity are few, but appear to show consistency in reduction of tissue-factor/platelet-dependent thrombin generation and thrombus formation. Blood spiked with rivaroxaban ex vivo showed reduced platelet aggregation induced by tissue factor and to a lesser extent induced by thrombin^{12,13}. Even at the very low dose of 2.5 mg b.i.d., rivaroxaban reduced platelet-dependent thrombin generation and coagulation-dependent thrombus-formation in patients treated with aspirin plus P2Y₁₂ inhibitor, whereas pure platelet-dependent thrombus formation was not affected¹⁴. Indeed, FXa inhibition appears to have no significant effect on platelets¹⁴ including in response to adenosine diphosphate, collagen, thrombin receptor-activating peptide or arachidonic acid¹⁵. Apixaban may therefore favourably enhance endogenous fibrinolysis through reduction in platelet-dependent and non-platelet dependent thrombin generation, which directly impact on the structure and stability of the thrombus and its resistance to fibrinolysis.

The benefit of apixaban on endogenous fibrinolysis was only observed with the Global Thrombosis Test and not with TEG. The fundamental difference between these techniques is that the GTT employs high shear to stimulate thrombus formation resulting in platelet activation and thrombin generation, whereas TEG is a haemostatic assay that measures the global viscoelastic properties of whole blood clot formation under low shear. This results in significant differences in the clot formed and therefore also in what the "lysis" assays measure. The GTT assesses the lysis and stability of a platelet thrombus, whereas in the TEG it reflects clot lysis. The GTT is particularly well-adapted to investigate the role of thrombin

17

inhibitors such as NOACs, primarily because thrombin generation from shear-activated platelets and fibrin stabilization of the initial platelet aggregates play a major role in determining the measured occlusion time³, whereas platelet-dependent thrombin generation is much less likely at the low shear rates in the TEG.

Nevertheless, the effect of NOACs on TEG parameters is contentious. Whilst some small studies reported that apixaban had minimal effect on TEG parameters, and that for the patients on apixaban, mean R value was within reference range representative of a normal population¹⁶, others have shown that spiking of blood with apixaban *in vitro* increased R time and time to maximal thrombus growth and coagulation¹⁷, prolonged clotting time and time to maximum velocity¹⁸. In the largest study assessing patients with NVAF with TEG, patients taking NOAC developed clot that was quicker to lyse than patients taking warfarin, and the rate of clot dissolution was faster in those on apixaban than in rivaroxaban, with 11 of 16 TEG indices showing a difference between those on aspirin, warfarin or a NOAC¹⁹.

Clinical implications

Our finding that that apixaban significantly improves endogenous fibrinolysis, particularly in patients with the longest lysis time at baseline, is significant and may be clinically important. The current data indicate that apixaban may have additional advantages over VKA or aspirin in patients with impaired endogenous fibrinolysis, although since we did not assess patients pre- and post-VKA or aspirin, we cannot be sure of the relative effects of apixaban on fibrinolysis compared to VKA or aspirin.

Our findings support the signals from clinical trials, showing that apixaban (rather than VKA or aspirin) may have additional advantages in high risk patients. Our data suggest that patients with impaired fibrinolysis may benefit more from apixaban to improve fibrinolysis, than

warfarin. Future studies are required to confirm whether patients with NVAF and impaired fibrinolysis are at increased risk of ischaemic stroke and systemic embolism, than those with effective fibrinolysis. If this is confirmed in large prospective studies, then patients with NVAF and impaired fibrinolysis may gain additional benefits from treatment with apixaban to favourably modulate endogenous fibrinolysis, than from VKA or aspirin.

Whether enhancing endogenous fibrinolysis with apixaban when this is impaired in patients with NVAF or even in acute coronary syndromes, can translate into a reduction in ischaemic events, and whether patients with prolonged LT derive greater benefit from apixaban than warfarin or other NOAC, requires further study.

Limitations

The main limitations of our study are the non-randomized, observational study design and the relatively small number of participants. The baseline LT in patients subsequently treated with apixaban was not uniform and therefore a greater effect of apixaban on LT may have been observed had we included more patients with impaired fibrinolysis at baseline. In the cross-sectional study, there were differences in clinical characteristics between the groups. Since fibrinolysis was not assessed before aspirin or warfarin treatment, we do not know the absolute magnitude of effect of these drugs on fibrinolysis, which may confound conclusion drawn about the observed shorter LT in patients on apixaban than on warfarin or aspirin. However, in contemporary clinical practice, few patients in the U.K. with NVAF are being started on VKA and therefore it would not have been logistically easy to compare patients pre- and post-VKA. Furthermore, whilst compliance was assessed in the apixaban and warfarin arms, it was not assessed in patients taking aspirin.

In conclusion, apixaban enhances endogenous fibrinolysis, with maximal effect in those with impaired fibrinolysis pre-treatment. Apixaban-treated patients exhibit more favourable fibrinolysis profiles than those taking warfarin or aspirin. Whether apixaban may confer additional thrombotic risk reduction in NVAF patients with impaired fibrinolysis, compared to warfarin, merits further study.

References

1. Taomoto K, Ohnishi H, Kuga Y, Nakashima K, Ichioka T, Kodama Y, et al. Platelet function and spontaneous thrombolytic activity of patients with cerebral infarction assessed by the global thrombosis test. Pathophysiol Haemost Thromb 2010;37:43–48.

2. Farag M, Spinthakis N, Gue YX, Srinivasan M, Sullivan K, Wellsted D, et al. Impaired endogenous fibrinolysis in ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention is a predictor of recurrent cardiovascular events: the RISK PPCI study. Eur Heart J 2019;40:295–305.

3. Okafor ON, Gorog DA. Endogenous Fibrinolysis: An Important Mediator of Thrombus Formation and Cardiovascular Risk. J Am Coll Cardiol 2015;65:1683–1699.

 Farag M, Niespialowska-Steuden M, Okafor O, Artman B, Srinivasan M, Khan A, et al. Relative effects of different non-vitamin K antagonist oral anticoagulants on global thrombotic status in atrial fibrillation. Platelets 2016;27:687–693.

 Gosselin RC, Adcock DM, Bates SM, Douxfils J, Favaloro EJ, Gouin-Thibault I, et al. International Council for Standardization in Haematology (ICSH) Recommendations for Laboratory Measurement of Direct Oral Anticoagulants. Thromb Haemost 2018;118:437– 450.

6. Connolly S, Eikelboom J, Joyner C, Diener HC, Hart R, Golytsin S et al. Apixaban in patients with atrial fibrillation. New Engl J Med 2011;364:806-817.

7. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al.
Apixaban versus warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981– 992.

8. Easton J, Lopes RD, Bahit M, Wojdyla DM, Granger CB, Wallentin L, et al. Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial. The Lancet Neurology 2012;11:503–511.

9. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta K, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in 'real-world' clinical practice. A propensity-matched analysis of 76,940 patients. Thromb Haemost 2017;117:1072–1082.

10. Posma J, Posthuma J, Ronk H. Coagulation and non-coagulation effects of thrombin. J Thromb Haemostasis 2016;14:1908–1916.

Wolberg AS. Thrombin generation and fibrin clot structure. Blood Reviews
 2007;21:131–142.

12. Wan H, Yang Y, Zhu J, Wu S, Zhou Z, Huang B, et al. An in-vitro evaluation of direct thrombin inhibitor and factor Xa inhibitor on tissue factor-induced thrombin generation and platelet aggregation: a comparison of dabigatran and rivaroxaban. Blood Coagul Fibrinolysis 2016;27:882–885.

13. Perzborn E, Heitmeier S, Laux V. Effects of Rivaroxaban on Platelet Activation and Platelet-Coagulation Pathway Interaction: In Vitro and In Vivo Studies. J Cardiovasc Pharmacol Therapeutics 2015;20:554–562.

14. Borst O, Münzer P, Alnaggar N, Geue S, Tegtmeyer R, Rath D, et al. Inhibitory mechanisms of very low-dose rivaroxaban in non-ST-elevation myocardial infarction. Blood Advances 2018;2:715–730.

15. Steppich B, Dobler F, Brendel L, Hessling G, Braun S, Steinsiek A, et al. Effect of the FXa inhibitors Rivaroxaban and Apixaban on platelet activation in patients with atrial fibrillation. J Thromb Thrombolysis 2017;43:490–497.

16. Bliden KP, Chaudhary R, Mohammed N, Muresan AA, Lopez-Espina CG, Cohen E, et al. Determination of non-Vitamin K oral anticoagulant (NOAC) effects using a newgeneration thrombelastography TEG 6s system. J Thromb Thrombolysis 2017;43:437–445.

17. Dias JD, Norem K, Doorneweerd DD, Thurer RL, Popovsky MA, Omert LA. Use of Thromboelastography (TEG) for Detection of New Oral Anticoagulants. Arch Pathol Lab Med 2015;139:665–673.

 Adelmann D, Wiegele M, Wohlgemuth RK, Koch S, Frantal S, Quehenberger P, et al. Measuring the activity of apixaban and rivaroxaban with rotational thrombelastometry. Thromb Res 2014;134:918–923.

19. Lau Y, Xiong Q, Shantsila E, Lip GY, Blann AD. Effects of non-vitamin K antagonist

oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation. J Thromb Thrombolysis 2016;42:535-44.

	Whole group Baseline Baseline Ba		Baseline	Baseline	Р	
		LT	LT	LT	LT	Value
		0-1500	1501-3000	3001-4500	4501-6000	
	(n=80)	(n=9)	(n=53)	(n=11)	(n=7)	
Age (yrs)	69.5±13.6	70.2±11.7	69.0±15.0	67.3±11.6	76.0±7.0	0.675
Male	43(54)	2(22)	33(62)	6(55)	2(29)	0.074
Weight (kg)	83.28±26.64	67.57±19.61	83.39±25.78	95.57±35.46	83.31±18.11	0.211
Height (cm)	169.00±14.21	163.77±9.47	172.00±11.35	160.90±25.79	165.71±7.86	0.085
BMI	27.93±6.50	24.80±5.25	27.68±6.73	30.31±5.96	30.00±6.01	0.819
Current smoker	5(6.3)	1(11)	3(5.6)	1(9)	0(0)	0.798
AF type						
Paroxysmal	71(88.8)	7(78)	47(89)	10(90)	7(100)	0.567
Persistent	9(11.2)	2(22)	6(11)	1(10)	0(0)	0.512
Hypertension	48(60)	4(44)	30(56)	9(82)	5(71)	0.293
Diabetes mellitus	11(13.8)	2(22)	7(13)	2(18)	0(0)	0.603
Hyperlipidemia	29(36.3)	3(33)	20(38)	5(45)	1(14)	0.583
Prior CAD	5(6.25)	0(0)	4(7.5)	1(9)	0(00	0.712
Prior MI	2(2.5)	0(0)	1(2)	1(9)	0(0)	0.484
Prior PCI	2(2.5)	0(0)	2(3.7)	0(0)	0(0)	0.790
Renal impairment	3(3.8)	1(11)	2(3.7)	0(0)	0(0)	0.562
Prior major bleeding	2(2.5)	0(0)	2(3.75)	0(0)	0(0)	0.790
Prior CVA	3(3.8)	0(0)	3(5.5)	0(0)	0(0)	0.662
LV impairment						
None	72(90)	7(77)	47(89)	11(100)	9(100)	0.308
Mild	5(6)	1(11)	3(5.5)	0(0)	0(0)	0.636
Moderate	2(2.5)	1(11)	1(1.8)	0(0)	0(0)	0.350
Severe	1(1.5)	0(0)	2(3.7)	0(0)	0(0)	0.790
CHA2DS2VASC score	3[1-4]	3[2-3]	2[1-4]	3[2-3]	3[2-3]	0.193

Table 1. Baseline clinical characteristics of patients in longitudinal study

HASBLED score	1[1-1]	1[1-1]	1[1-1]	1[0-1]	1[1-2]	0.128
Concomitant medication						
Statin	29(36)	4(44)	20(38)	4(36)	1(14)	0.621
Beta blocker	21(26)	1(11)	14(26)	5(45)	1(14)	0.298
CCB blocker	23(28.75)	2(22)	12(23)	5(45)	4(57)	0.144
PPI	17(21.25)	2(22)	11(21)	2(18)	2(29)	0.960
Metformin	6(7.5)	1(11)	4(7.5)	1(9)	0(0)	0.855
Baseline blood tests						
Haemoglobin (g/L)	138±19	127±18	139±20	144±9	134±19	0.118
Haematocrit (%)	41±5	38±5	41±5	43±3	40±7	0.151
Platelet count	257±85	296±76	248±85	249±28	281±141	0.259
(x10 ⁹ /L)						
White cell count	8.7±2.7	7.7±1.8	8.8±2.4	8.4±3.2	9.1±5.6	0.583
(x10 ⁹ /L)						
eGFR	72±16	74±21	71±16	77±14	65±11	0.261
Fibrinogen (g/L)	4.5±1.5	3.6±0.5	4.4±1.5	4.8±0.9	5.8±1.7	0.122
PT (sec)	12.0±1.4	11.5±1.3	12.0±1.4	12.1±1.7	11.5±0.9	0.748
aPTT (sec)	28.6±3.3	28.6±4.0	28.0±2.2	31.0±6.2	29.2±3.0	0.411
CRP (mg/L)	4.8±6.6	2.3±2.2	5.4±7.7	3.2±2.8	7±5	0.182
OT at baseline (sec)	361±112	377±126	360±110	376±109	324±130	0.740
LT at baseline (sec)	2204	1425	2114	3427	5166	<0.001
	[1779-2738]	[1350-1454]	[1800-2347]	[3099-3667]	[4843-6000]	
OT on treatment (sec)	463±124	501±98.4	452±118	542±151	376±88	0.038
LT on treatment (sec)	1882	1367	1866	2322	2707	<0.001
	[1607-2374]	[1206-1607]	[1631-2312]	[1975-3345]	[1710-3285]	

Values are mean \pm SD or median[IQR] and n(%).

BMI: body mass index, AF: atrial fibrillation, CAD: coronary artery disease, CCB: calcium channel blocker, MI: myocardial infarction, PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, CVA: cerebrovascular accident, Renal impairment defined as estimated glomerular filtration rate (eGFR)<60; AF type(34); Left ventricular function classification: Mild 45-55% ejection fraction, Moderate 35-45% ejection fraction, Severe <35% ejection fraction.

CHA₂DS₂VASc score in AF and HAS-BLED bleeding risk, please see references (35, 36). Normal values: haemoglobin 130-180 g/L in males and 115-165 g/L in females; haematocrit 40-52% in males and 36-47% in females; platelet count 150-400 x10⁹/L; white cell count 4-11 x10⁹/L; eGFR >60; fibrinogen 1.8-5.4 g/L; PT 11-13.5 seconds; aPTT 25-35 seconds; C-reactive protein 0-5 mg/L.

	Whole group	Apixaban	Warfarin	Aspirin	P Valu
	(n=180)	(n=60)	(n=60)	(n=60)	
Age (yrs)	73.8±12.1	69.6±13.4	74.6±9.7	77.1±12.0	0.248
Male	105(58)	33(55)	35(58)	37(62)	0.636
Weight (kg)	82.37±21.22	83.70±27.15	83.62±18.01	79.80±17.16	0.573
Height (cm)	169.48±11.87	168.45±15.68	171.11±8.83	168.88±9.97	0.567
BMI	28.00±5.60	28.25±7.08	28.13±5.03	27.60±4.35	0.652
Current smoker	11(6)	5(8)	4(7)	2(3)	0.598
AF type					
Paroxysmal	138(76)	54(90)	35(60)	48(80)	0.001
Persistent	28(16)	6(10)	12(20)	10(17)	0.115
Hypertension	122(68)	37(62)	42(70)	43(70)	0.454
Diabetes mellitus	33(18)	9(15)	12(20)	12(20)	0.716
Hyperlipidemia	99(55)	26(43)	31(52)	42(70)	0.011
Prior CAD	44(24)	3(5)	20(33)	21(35)	<0.001
Prior MI	20(11)	2(3)	10(17)	8(13)	0.054
Prior PCI	15(8)	2(3)	9(15)	4(6)	0.059
Renal impairment	18(10)	2(3)	7(12)	9(15)	0.090
Prior major bleeding	7(4)	2(3)	5(8)	0(0)	0.059
Prior CVA	25(14)	3(5)	11(18)	11(18)	0.051
Prior LV impairment					
None	150(83)	54(90)	47(78)	49(82)	0.090
Mild	15(8)	3(5)	6(10)	6(10)	0.253
Moderate	9(5)	1(2)	6(10)	2(3)	0.147
Severe	6(4)	2(3)	1(2)	3(5)	1.000
CHA2DS2VASC score	3[2-4]	3[1-4]	4[2-5]	4[3-5]	0.945
HASBLED score	1[1-2]	1[1-1]	1[1-2]	1[1-2]	0.388

Table 2. Baseline clinical characteristics of patients in cross-sectional study

Concomitant medication

Statin	107(59)	25(42)	40(66)	42(70)	0.003
Beta blocker	92(51)	15(25)	11(18)	15(25)	<0.001
ССВ	44(24)	18(30)	11(18)	15(25)	0.329
PPI	68(38)	13(22)	26(43)	29(48)	0.006
Metformin	19(11)	5(8)	7(12)	7(12)	0.790
Baseline blood tests					
Haemoglobin (g/L)	134±17	138±18	132±15	133±16	0.428
Haematocrit (%)	40±5	41±5	40±4	40±4	0.743
Platelet count (x10 ⁹ /L)	227±72	235±55	215±85	229±72	0.052
White cell count (x10 ⁹ /L)	7.6±2.0	7.9±2.1	7.1±1.9	7.7±2.0	0.093
eGFR	67±16	70±16	66±16	65±17	0.139
Fibrinogen (g/L)	4.5±1.1	4.4±1.4	4.5±1.0	4.5±0.9	0.402
PT (sec)	17.7±9.1	12.0±1.4	29.5±6.7	12.3±2.3	<0.001
aPTT (sec)	32.0±7.3	28.3±3.3	38.8±7.3	29.0±5.4	<0.001
CRP (mg/L)	5.5±10.6	4.7±6.4	4.0±3.6	7.4±16	0.872

Values are mean \pm SD or median[IQR] and n(%).

BMI: body mass index, AF: atrial fibrillation, CAD: coronary artery disease, CCB: calcium channel blocker, MI: myocardial infarction, PCI: percutaneous coronary intervention, PPI: proton pump inhibitor, CVA: cerebrovascular accident, Renal impairment defined as estimated glomerular filtration rate (eGFR)<60; AF type(34); Left ventricular function classification: Mild 45-55% ejection fraction, Moderate 35-45% ejection fraction, Severe <35% ejection fraction.

CHA₂DS₂VASc score in AF and HAS-BLED bleeding risk, please see references(35, 36). Normal values: haemoglobin 130-180 g/L in males and 115-165 g/L in females; haematocrit 40-52% in males and 36-47% in females; platelet count 150-400 $\times 10^9$ /L; white cell count 411 x10⁹/L; eGFR >60; fibrinogen 1.8-5.4 g/L; PT 11-13.5 seconds; aPTT 25-35 seconds; C-reactive protein 0-5 mg/L.

Table 3. TEG indices

Reaction Time (R) [min]	Measures the time from the start of a sample run until the first
	significant level of detectable clot formation. R reduces in
	hypercoagulable conditions
Kinetics (K) [min]	Measures the time from R until a fixed level of clot strength is
	reached. K is shortened in hypercoagulable conditions.
Angle	Represents the rate of clot formation and reflects fibrinogen
	activity. Angle relates to K. Both represent the rate of clot
	formation. Angle is larger in hypercoagulable conditions
Maximum Amplitude	Represents whole clot strength and reflects many aspects of clot
	formation including platelet number and function as well as the
(MA) [mm]	fibrin contribution to clot strength. MA is larger by
	hypercoagulable conditions
LY30 [%]	Represents the percentage of clot which has lysed after 30
	minutes of MA
LY60 [%]	Represents the percentage of clot which has lysed after 60
	minutes of MA
Time to Maximum	Measures the time to form maximum clot strength
Amplitude (TMA) [min]	
Clot Lysis Time (CLT)	Measures the time to 2mm amplitude reduction from MA.
	The astrony and the to 211111 an private reduction from WIA.
[min]	

	Baseline	Apixaban	P value
	(n=80)	(n=80)	
OT (sec)	361±112	463±124	<0.0001
LT (sec)	2204[1779-2738]	1882[1607-2374]	0.0003
Reaction Time (R) [min] native	7.8[5.4-11.4]	8.9[6.1-12.2]	0.398
Reaction Time (R) [min] kaolin	4.2[2.6-5.6]	4.8[3.2-6.3]	0.159
Kinetics (K) [min] native	3.6[2.6-5.8]	4.2[3.0-7.2]	0.096
Kinetics (K) [min] kaolin	1.4[1.1-2.2]	1.7[1.4-2.3]	0.113
Angle [°] native	43.0[39.0-47.0]	42.0[38.0-45.0]	0.552
Angle [°] kaolin	68.4[65.0-72.0]	67.0[58.0-70.0]	0.026
Maximum Amplitude (MA) [mm] native	34.5[27.3-48.3]	34.6[29.6-49.8]	0.535
Maximum Amplitude (MA) [mm] kaolin	21.0[17.8-25.0]	23.3[20.0-25.9]	0.068
LY30 [%] native	0.1[0.0-3.1]	0.0[0.0-0.4]	0.276
LY30 [%] kaolin	1.9[0.3-5.4]	0.4[0.0-2.0]	0.066
LY60 [%] native	1.4[0.0-5.8]	0.5[0.0-3.0]	0.405
LY60 [%] kaolin	4.2[1.9-9.9]	2.6[1.0-4.6]	0.067
Time to Maximum Amplitude (TMA)	34.5[27.3-48.3]	34.6[29.6-49.8]	0.535
[min] native			
Time to Maximum Amplitude (TMA)	21.0[17.8-25.0]	23.3[20.0-25.9]	0.068
[min] kaolin			
Clot Lysis Time (CLT) [min] native	60.6[59.4-61.5]	60.15[57.7-61.2]	0.155
Clot Lysis Time (CLT) [min] kaolin	60.8[59.5-61.7]	60.8[59.7-61.5]	0.780

Table 4. Difference in GTT and TEG parameters in response to apixaban

Table 5. Thrombotic parameters in patients taking apixaban, warfarin and aspirin


OT=occlusion time, LT= lysis time, R=reaction time, K=kinetics, MA=maximal amplitude,

TMA=time to maximal amplitude, CLT=clot lysis time.

	Apixaban	Warfarin	Aspirin	Three group compari son	Apixaban vs. warfarin +aspirin	Apixaban +warfarin vs. aspirin	Apixaba n vs. Warfari
	(n=60)	(n=60)	(n=60)	P value	P value	P value	n P value
OT (sec)	463±131	589±154	430±121	0.126	0.054	0.025	<0.0001
LT (sec)	1850	2758	2135	0.0001	<0.0001	0.465	<0.0001
	[1591-2300]	[2014-3502]	[1752-2463]				
R [min] native	8.8[5.7-12.3]	13.0[8.7-17.8]	8.8[6.0-12.2]	0.001	0.059	0.067	0.0007
R [min] kaolin	4.7[3.0-6.8]	6.5[4.9-10.4]	3.0[2.0-5.0]	0.0001	0.843	0.0002	0.006
K [min] native	4.4[3.0-7.2]	5.4[3.4-7.5]	4.0[2.6-6.1]	0.076	0.954	0.0517	0.212
K [min] kaolin	1.7[1.4-2.2]	2.0[1.5-2.7]	1.5[1.2-2.7]	0.152	0.789	0.0367	0.265
Angle [°] native	45.3[30.7-52.1]	33.0[26.2-47.9]	46.0[33.0-59.0]	0.009	0.793	0.011	0.050
Angle [°] kaolin	70.0[57.0-69.0]	61.0[47.0-69.0]	67.3[60.0-72.0]	0.152	0.839	0.084	0.265
MA [mm] native	70.0[64.0-76.0]	69.0[56.0-75.0]	69.0[62.0-75.0]	0.673	0.386	0.830	0.347
MA [mm] kaolin	76.0[72.0-80.0]	75.0[72.0-79.0]	75.0[73.0-79.0]	0.872	0.632	0.819	0.703
LY30 [%] native	0.0[0.0-0.9]	0.0[0.0-1.3]	0.0[0.0-1.1]	0.841	0.810	0.744	0.980
LY30 [%] kaolin	0.4[0.0-2.0]	0.6[0.0-3.9]	1.2[0.3-2.4]	0.872	0.264	0.293	0.520
LY60 [%] native	0.6[0.0-3.1]	0.5[0.0-5.6]	1.3[0.1-4.7]	0.744	0.598	0.542	0.993
LY60 [%] kaolin	2.6[1.0-5.0]	3.0[1.0-9.5]	4.2[2.1-5.9]	0.588	0.321	0.388	0.532
TMA [min] native	35.0[30.0-50.0]	37.0[32.0-49.0]	32.0[26.0-43.0]	0.064	0.874	0.037	0.253
TMA [min] kaolin	24.0[20.0-26.0]	26.0[22.0-30.0	21.0[16.0-23.0]	0.001	0.798	0.001	0.0511
CLT [min] native	60.0[45.0-61.0]	61.0[57.0-62.0]	61.0[59.0-61.0]	0.036	0.011	0.100	0.055
CLT [min] kaolin	61.0[60.0-62.0]	61.0[60.0-62.0]	60.8[60.4-61.4]	0.998	0.956	0.889	0.883

Figure 1. Effect of apixaban on occlusion time and lysis time

(A) Distribution of OT before and after apixaban treatment. (B) Distribution of LT before and after apixaban treatment. Apixaban significantly prolonged OT as evidenced by rightward shift (reduction in platelet reactivity). LT was significantly reduced as evidenced by leftward shift (representing faster lysis).







Figure 2. Effect of apixaban on lysis time according to baseline LT

The effect of apixaban on LT was particularly marked in patients with longest baseline LT.



35